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Background: As we are living in the era of antibiotic overuse, antibiotic 
associated diarrhea (AAD) is considered now a distinct health problem with a 
need for more attention. 
Aim of the Study: was to perform a highly specific detection and definition of 
pathogenic Clostridium perfringens and Clostridium difficile related AAD in 
children compared to adults and geriatircs.
Patients and Methods: One hundred and fifty patients diagnosed for AAD 
were included in this study (50 children, 50 adults and 50 geriatric patients). 
All of them were subjected to full medical history including complete therapeutic 
history of antibiotics and collection of stool sample during the attack for 
detection of Clostridium perfringenes enterotoxin (CPEnt) and Clostridium 
difficile cytotoxin by (EIA) kit. PCR detection of Clostridium perfringenes cpe 
gene (Coding gene for CPEnt) was performed as well.
Results: Results showed that prevalence of Clostridium difficile cytotoxin was 
24% while Clostridium perfringenes enterotoxin was 12% as detected by EIA 
in faecal specimens as a whole. Detection of cpe gene by PCR was positive in 
16% of all cases. Children (OR: 4.2, 95% CI: 1.3-14.8, P_0.01) and geriatric 
patients (OR: 3.4, 95% CI: 1.2-13.5, P_0.02) were significantly more prone to 
Clostridium difficile AAD compared to adults. Also, childhood was a significant 
risk for Clostridium perfringens AAD (OR: 2.1, 95% CI: 0.54-7.4, P_0.04).
In Conclusion: children and geriatric patients are more vulnerable to develop 
AAD with antibiotic abuse compared to adults.
Abbreviations: AAD=Antibiotic associated diarrhea, CI=Confidence interval, 
ELISA=Enzyme-linked immunosorbent assay, OR=Odd ratio, PCR=Polymerase 
chain reaction.
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INTRODUCTION                                                                     
Antimicrobial agents are the most 
frequently prescribed medicines in 
children, because acute infectious 
diseases are prevalent in this age 
group. The demonstration that acute 
infections are primarily of viral origin 
has not reduced the use of antibiotics, 
nor has the fact that antibiotics afford 
only marginal alleviation of the clinical 
symptoms.1
Antimicrobial treatment may disturb 
the colonization resistance of 
gastrointestinal micro flora, which 
may induce clinical symptoms, most 
commonly diarrhea. The incidence 
of diarrhoea in children receiving 
antimicrobial treatment is unclear.2 
The discrepancies in the incidence may 
have been attributable to differences 
in the definition of diarrhoea, the 
antimicrobial agent used, the number 
of daily doses, the duration of the 
treatment, and the time from previous 
antimicrobial treatments.3 
The severity of antibiotic-associated 
diarrhoea  may range from a brief, 
self-limiting disease to devastating 
diarrhea with electrolyte disturbances, 
dehydration, crampy abdominal pain, 
pseudomembranous colitis, toxic 
megacolon, or even death.4
The objective of this cross sectional 
controlled study was to evaluate the 
molecular incidence of Clostridium 
Perfringens and Clostridium Difficile 
related diarrhea after antimicrobial 
treatment in children compared to adults 
and geriatrics.
PATIENTS AND METHODS                                   
Patients:
Antimicrobial agents were prescribed 
for the treatment of all the included 
subjects in the hospital.
Children age (<18 years) ranged from 
2 weeks to 17.8 years of age (Mean: 
4.5 years, Median: 6 years of age). 
Adult age (18-60 years) ranged from 19 
years to 53 years old (Mean: 32 years, 
Median: 34 years) and geriatric age 
(Over 60 years) with mean; 65 years 
and median; 68 years.
All study subjects met the inclusion 
criteria: they had not received any 
antimicrobial medication during the 
previous 2 weeks before admission, 
they did not suffer from gastrointestinal 
disorders, and they all needed 
antimicrobial treatment, for different 
non gastrointestinal indications. 
All of them were hospitalizedat Ain 
Shams University Hospitals and had 
diarrhoea≥3 days post admission. 
Fifty two hospitalized patients 
(Children, adults and geriatrics) were 
included as controls. All of them had 
received antimicrobial therapy within 2 
weeks without developing diarrhea.
Study Design:
All patients received the same 
information and the follow-up was 
conducted in a similar manner. A daily 
symptom diary recorded stool frequency 
and consistency (Solid, loose, watery). 
Diarrhoea was defined as at least three 
watery or loose stools per day for a 
minimum of 2 consecutive days within 
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2 weeks from antimicrobial intake. 
In the case of diarrhea, the parents 
were requested to bring a fecal sample 
for analysis. The primary outcome 
measure was “Diarrhoea during the 
first 2 weeks after the beginning of the 
antimicrobial treatment”, because this 
period most likely reflects the effects of 
antimicrobial use. 
The parents/patients were informed 
verbally and in writing about the nature 
and requirements of the study. Written 
informed consent was obtained from 
the parents/patients, and the study was 
approved by the ethics committees of 
Ain Shams University Hospital.
Collection of patients and controls data 
included; demographics, admission 
details, lengths of hospital stay 
before diarrhea, and histories of non 
antibiotic (Antacids, cytotoxics, and 
gut stimulants) and detailed antibiotic 
drug administration and procedures 
undertaken (Endoscopy, enema, feeding 
tube insertion, and surgery) within the 
14 days before the onset of symptoms.
Samples:
Stool specimens were obtained from 
patients and controls. For patients, 
only diarrhoeal faecal specimens (i.e. 
those that adopted the contours of the 
vessel) were included in the study. Stool 
specimens were cooled immediately 
at 6°C to 8°C and within 24 hours the 
stool specimen was divided into three 
compartments:
Part 1: inoculated on thioglycolate 
broth, incubated aerobically at 37ºC for 
24 hours, then subcultured on Colombia 
blood agar (Oxoid) with a 5μg 
metronidazole disc (Oxoid), and Egg 
yolk agar (Oxoid), both were incubated 
anaerobically 48 hours at 37ºC.
Part 2: inoculated into distilled water 
and then centrifuged, supernatant was 
taken in aliquot tubes, stored at -20ºC 
for further detection of Cl. difficile 
cytotoxin A/B and Cl. perfringenes 
enterotroxin with EIA supplied by 
Biopharm, Germany.
Part 3: inoculated into Phosphate 
Buffered Saline with glycerol 40%, 
then centrifuged and the supernatant 
was taken to aliquot tubes and stored at 
-20ºC for further DNA extraction and 
nested PCR for detection of cpe gene.
Microbiological analysis of samples:
(i) Toxin detection in feces:
All samples were tested for C. difficile 
cytotoxin and C. perfringens enterotoxin 
by RIDASCREEN kits supplied by 
Biopharm, Germany. They are enzyme 
immunoassays for the detection of 
cytotoxin A and B of Clostridium 
difficile and Cl. perfringenes enterotoxin 
in stool samples. The cutoff was 
calculated, any test sample more than 
10% above it was considered+ve and 
any sample below it was considered-ve. 
Enzyme-linked immunosorbent assay 
(ELISA) kit was used according to the 
manufacturer’s instructions.
(ii) Culture of Clostridium Perfringens 
and Clostridium Difficile:




- Lecithinase activity. According to 
Collee.5
(iii) Molecular finger printing cpe gene 
analysis: 
DNA was extracted directly from each 
faecal specimen with QIAamp DNA 
stool Mini Kit «QIAGEN, Crawley, 
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UK» according to manufacturer’s 
instructions. DNA extracts were stored 
at -20ºC before PCR. The first round 
primers were 5̀̀̀̀-TGTTAATACTTAAG 
GATATGTATCC-3 and 5-TCCA-
TCACCTAAGGACTG-3̀ as described 
by Asha and Wilcox.6
The reaction combrised 5 min. at 
94ºC followed by 34 cycles of 1 min. 
at 94ºC, 1 min. at 50ºC and 1 min. at 
72ºC. there was a final extension step 
of 10 min. at 72ºC. The PCR product 
was used as a template for the second 
round PCR. Second round primers 
were: 5̀ATGTAATAGATAAAGGAGA 
TGGTT-3̀ and ATAAATTCAG 
AAGTAAATCCAACT-3̀. The reaction 
comprised 5 min. at 95ºC followed by 
45 cycles of 30s at 94ºC, 30s 50ºC and 
30s at 70ºC. The PCR product was 163 
bp. The enterotoxigenic C. perfringenes 
strain NCTC was used as the positive 
control for PCR assays.
Statistical Methods:
The results are presented as means with 
range. The x2 test, Wilcoxon signedrank 
test, and analysis of variance for repeated 
measurements were used in statistical 
comparisons. Statistical analyses were 
conducted using SPSS (SPSS Inc., 
Chicago, version II.) software and Epi 
Info (Window version; 3.3.2- 2005) 
software. Age and gender data were 
analyzed by comparison of cases with 
the overall study population by use 
of multinomial logistic regression. 
Other risk factors were assessed using 
conditional backwards multivariate 
logistic regression with matched data.
RESULTS                                                                       
AAD Pathogens:
At least one AAD pathogen was 
detected in 51 of 150 (34%) AAD faecal 
samples. C. difficile cytotoxin and/or C. 
perfringens enterotoxin were detected 
in 24% (no-36/150) and 12% (no-
18/150) of samples, respectively. Three 
samples (5.8% of positive specimens) 
had evidence of both C. difficile and C. 
perfringens. Of the (36/150) C. difficile 
cytotoxin positive specimens, 30 (83%) 
samples yielded positive culture, and 
of (18/150) C. perfringens enterotoxin 
positive samples, only 12 (67%) yielded 
positive culture for C. perfringens.
(a) EIA results are shown in (Table 1):
Table 1: Cl. difficile and Cl. perfringenes EIA-results:































(b) Molecular finger printing:
Table (2) showed comparison between 
results obtained by EIA result was 
18/150+ve cases (12%) while by PCR 
the result was 24/150+ve cases (16%), 
which was not significantly different 
(OR: 0.72, 95% CI: 0.35-1.45; P- 
0.41) table (2). Of the 24 positive PCR 
cpe gene fecal specimens, 11 were 
detected in children, 6 in adults and 7 
in geriatrics.
Analysis of risk factors:• 
Pediatric patients and those more than 
60 years of age had a significantly 
increased risk of infective AAD (Odds 
ratios [OR], 3.61 and 2.98, respectively; 
P-0.001) compared to adults. This 
age related risk was consistent for C. 
difficile (OR: 4.2, 95% CI: 1.3-14.8, 
P-0.01 in children) and (OR: 3.4, 95% 
CI: 1.2-13.5, P-0.02 in geroatrics). The 
agerelated risk for C. perfringens was 
documented only in pediatric patients 
Table 2: Comparison between EIA and PCR as different diagnostic methods for detection of toxigenic 
Cl. perfringenes (Using Mann Whitney U test).
EIA
No.   %
PCR
No.   % Z P
OR
(95%CI)




- ve cases 132  88% 126  84%
(OR, 2.1, 95% CI: 0.54-7.4, P-0.04), 
but no significant agerelated risk was 
detected in geriatrics. Gender was not 
an independent risk factor for infective 
AAD (P-0.74), also there was no 
significant agesex interaction (P-0.46). 
Significant results from the conditional 
multiple logistic regression analyses 
for infective ADD development were 
assessed. The major risk factors for 
infective AAD were administration of 
cytotoxic drugs and broad spectrum 
cephalosporins [OR (95%CI): 8.933 
(7.28–10.59) and 2.511 (1.87–3.15) 
respectively]. 
We found that 32% of AAD cases 
in this study were associated with 
using broad spectrum penicillins as 
ampicillin, amoxicillin-clavulanate 
[OR 2.277 (1.22–4.1)], 30% of cases 
were associated with cephalosporins 
and 16% with both types [OR 2.594 
(2.84–5.61)]. 
The mean length of hospital stay prior 
to the onset of diarrheal symptoms was 
significantly longer for patients than for 
controls (19.2+4.1 versus 10.5+3.7 days; 
paired t test, t-3.91; df-154; P-0.01) – 
OR (95% CI) 1.017 (1.01–1.03).
DISCUSSION                                                                     
The most common complication of 
antimicrobial therapy is antibiotic-
associated diarrhea.6 It is likely that a 
substantial proportion of AAD cases are 
not due to infective causes and instead 
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represent either direct gut toxicity of 
antibiotics or other medical etiologies. 
Nevertheless, studies of the infective 
aetiology of AAD have concentrated 
almost solely on C. difficile, and thus, in 
the great majority of cases, a pathogen 
has not been identified.7 
We chose to analyze only the diarrhea 
episodes that occurred during the first 
2 weeks after the beginning of the 
antimicrobial treatment, because the 
later that diarrhea occurs, the more 
unlikely it is caused by an antimicrobial 
agent.8 
C. difficile was the predominant 
infective cause of AAD and was 
approximately from 4 to 60 times more 
common than C. perfringens in many 
studies.7-9 In this study, for every 10 
cases of C. difficile AAD, we identified 
5 cases of C. perfringens AAD, most of 
them were children. However, we did 
not consider other putative infective 
causes of AAD, such as Candida and 
Klebsiella species, because of the given 
relatively weak evidence base for these 
organisms as pathogens.10,11
In the present study prcentage of 
toxigenic Cl. difficile detection by 
EIA in stool samples of hospitalized 
diarrheal patients was 24% (36/150) 
[Divided as 16 patients from children 
group, 5 patients from adult group and 
15 patients from geriatric group] versus 
0% (No isolation of Cl. difficile from 
controls).
Many studies reported that carriage of 
Cl. difficile is common among antibiotic 
treated hospitalized patients, as it was 
detected in 32% of faecal specimens 
from AAD in Johnston et al.12
Our results agreed with10,13-15 who 
reported that Cl. difficile prevalence 
ranged from 15-25% of hospitalized 
patients receiving antibiotics. 
Our data add to the evidence base that 
C. perfringens is a significant cause 
of nosocomial AAD.1,12 Laboratory 
identification of such cases can be 
justified in at least two ways. First, 
antibiotic treatment of C. perfringens 
AAD may aid symptom resolution.16 
While there are no data to determine 
optimal therapy, it is plausible 
that either oral metronidazole or 
vancomycin could be effective. Second, 
as discussed below, diagnosis of cases 
could be important to identify clusters 
and/or limit nosocomial transmission. 
ELISA-ased methods should therefore 
be employed to optimize the laboratory 
diagnosis of C. perfringens AAD.17,18
The ELISA-negative PCRpositive 
samples may represent a group 
of  patients who are carrying 
enterotoxigenic C. perfringens but in 
whom CPEnt is not produced. Thus, 
the cpe gene may be present but not 
expressed. Alternatively, CPEnt may 
not be captured by the ELISA system, 
for example, if it was a modified toxin 
or neutralised by host factors.19
Interesting enough, children have a 
significant more risk to develop C. 
perferingens AAD compared to adults 
and geriatrics. This could be related to 
the intestinal internal environment and 
the innate resistance of anaerobic gut 
flora specific for children.10
Many AAD risk factors studies have 
been flawed due to limited size, poor 
choice of controls and thus potential for 
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confounding, and choice of laboratory 
methodology.20 Also, most previous 
studies have focused solely on C. 
difficile as the etiological agent.21 Our 
study was designed to address these 
deficiencies. Confounding factors 
were reduced by matching cases and 
controls for date and location. Times 
and locations were matched to account 
for possible fluctuations in C. difficile 
endemicity, particularly the prevalence 
of environmental contamination and 
thus the risk of patient and healthcare 
worker exposure.22 
However, matching of patient locations 
did provide some basic adjustment for 
this potential confounding variable. 
Controversy about optimal control 
populations for AAD risk factor studies 
was highlighted in a recent systematic 
review.23
It is recognized that the risk of 
AAD can be reduced by substituting 
the administration of highrisk 
antibiotics, such as broadspectrum 
cephalosporins and clindamycin13, 
with relatively lowrisk drugs such as 
penicillin, trimethoprim, gentamicin17, 
ciprofloxacin24, and ureidopenicillins.21
Identifying additional risk factors for 
AAD permits interventions to reduce 
disease burden. Risk factors identified 
for AAD are influenced greatly by risk 
factors specific to C. difficile AAD due 
to the predominance of this pathogen.25 
Notably, each additional day of hospital 
stay equated to an 2% increased 
risk of infection.7 However, some 
studies have pointed to a protective 
effect of broad spectrum penicillin 
and Aminoglycosides, as they were 
associated with a reduced risk of overall 
AAD, which was probably related to 
the innate resistance of anaerobic gut 
flora.12 
Recent data suggest that broadspectrum 
cephalosporins may stimulate toxin 
production by C. difficile.15 Also, 
increasing evidence points to the 
importance of the antibiotic resistance 
of C. difficile.18 The roles of such 
factors in C. perfringens AAD remain 
to be elucidated. 
Our data suggest that a limited number 
of C. perfringens genotypes cause 
the majority of AAD cases, although, 
unlike what is seen for C. difficile, there 
is no predominant genotype.26 
We did not examine the environment 
for C. perfringens, but it is feasible 
that spore contamination similar to that 
seen in areas of C. difficile endemicity 
occurs secondary to fecal soiling by 
incontinent patients.23
Strains with serotypes the same as 
those of fecal isolates were found in the 
hospital environment and on the hands 
of infected patients during an outbreak 
of C. perfringens diarrhea.26 
This is further evidence that C. 
perfringens may be acquired 
nosocomially. It is likely that measures 
to limit nosocomial dissemination of 
C. difficile, including case isolation and 
attention to environmental hygiene, 
will also be of benefit in the treatment 
of enterotoxigenic C. perfringens.
The most effective way to prevent 
antibiotic-associated diarrhea which is 
evident to be more risky for children 
and geriatrics is still critical use of 
antimicrobials, as recommended 
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recently for the evidenced based 
treatment of children. However, when 
antimicrobial treatment is indicated, 
Lactobacillus GG could be a novel 
promising adjunctive therapy18,23 to 
prevent diarrhea. Further randomised 
controlled studies are clearly required 
here.
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